A year after being infected with coronavirus, those affected are much more likely to suffer from typical long Covid symptoms, such as fatigue, than people who have never had a positive PCR test for coronavirus. This greater prevalence cannot be attributed to mental stress as a result of the pandemic. This is shown by the findings of the Swiss Corona Stress Study, conducted with more than 11,000 participants by the University of Basel.
The European Research Council (ERC) awards four researchers from the University of Basel with one of the coveted ERC Consolidator Grants. The projects in the fields of cell biology, physics, immunology and chemistry will each receive around two million euros in funding.
Technological devices have become constant companions in our daily lives. For the first time, researchers at the University of Basel have now collected data to investigate whether smartwatches can be used to help with compulsive hand washing. Initial results are “cautiously promising.”
Prof. Silvia Arber from the Biozentrum, University of Basel, and at the Friedrich Miescher Institute for Biomedical Research receives the renowned Brain Prize 2022. With this award, the Lundbeck Foundation recognizes this year's three prizewinners for their pioneering research into the neuronal circuits that control movement.
There is no other place where so many Neolithic pile dwellings have been uncovered as around the Alps. It is a mystery, however, how this “building boom” came to be. Researchers at the University of Basel have now uncovered new clues, and say that settlers at Lake Varese in northern Italy may have played a leading role.
The University of Basel is following with great concern the developments in Ukraine following Russia's military intervention, directed not only against the sovereignty and self-determined development of a country, but also against the democratic and liberal growth of a young European state.
The University of Basel will offer two new online courses this spring semester: «Examining African Contributions to Global Health» and «Gender and Labour in the Global South». Both courses are available free of charge to interested participants via the online platform FutureLearn.
Prof. Markus Rüegg and Dr. Judith Reinhard from the Biozentrum of the University of Basel have founded the start-up SEAL Therapeutics AG together with Dr. Thomas Meier, former CEO of Santhera Pharmaceuticals. Their goal is to treat congenital muscular dystrophy using gene therapy and to bring their research findings from the laboratory to the patient. To date, there is no treatment for this life-threatening genetic disease.
The spin-off Aukera Therapeutics, which was founded at the Biozentrum last year, has been selected for the start-up accelerator program BaseLaunch. The biotech company develops novel therapies for patients suffering from mTOR related diseases such as cancer and neurodegenerative diseases. mTOR plays a key role in cell growth control.
